The stock price has soared!

On October 8, the first trading day after the National Day holiday, Hengrui Pharmaceuticals stock price ushered in a long-lost surge.

Recently, Dr.

The journey of internationalization is more interesting

According to Joseph E.

During the more than 8 years of Merck's role as vice president and head of global medical affairs for oncology, Joseph E.

As the former senior vice president and head of global medical affairs of Bristol-Myers Squibb, Joseph E.

From the perspective of the industry, only when innovative drugs enter the international market can they fully reflect their clinical value and give enterprises a large R&D return

At present, Hengrui Medicine has launched 8 innovative drugs including carrelizumab, errecoxib, and apatinib mesylate in China, and more than 50 innovative drugs are under clinical development and more than 240 clinical drugs Experiments are carried out at home and abroad

Parallel to the innovation strategy is Hengrui Pharmaceutical’s internationalization strategy.

Sun Piaoyang's second helm has made Hengrui Pharmaceuticals, which is the leader in medicine, more and more eye-catching.

Local pharmaceutical companies accelerate their pace of "going out to sea"

In fact, under the combination of policies such as drug review reform, mass procurement of drugs, and reform of medical insurance payment methods, local pharmaceutical companies are accelerating the transformation from the traditional image of raw materials and generic drugs to innovative drug "players"

At the beginning of this year, Junshi Biosciences and Coherus BioSciences reached a cooperation on the development and commercialization of its self-developed anti-PD-1 monoclonal antibody drug triprolizumab in the United States and Canada.

Coincidentally, BeiGene also announced in January this year that it has reached a cooperation and licensing agreement with the global pharmaceutical giant Novartis on the development, production and commercialization of its self-developed anti-PD-1 antibody drug tislelizumab in multiple countries , The down payment is as high as 650 million U.

However, BeiGene's $2.

Some insiders pointed out that as the leading traditional medicine companies go through the painful period of transformation, the strong R&D capabilities they have accumulated and cultivated will continue to show in the future

At present, China is in the process of leaping from a major pharmaceutical country to a powerful pharmaceutical country.